ASB17061 / Daiichi Sankyo, Invea Therap - LARVOL DELTA

ASB17061, a novel chymase inhibitor, prevented the development of angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice. (PubMed, Eur J Pharmacol) - "An intraperitoneal injection of mMCP-4 induced the accumulation of pro-MMP-9-producing cells including CD11b  Gr-1  cells. Taken together, these data indicate that ASB17061 is a promising novel oral therapeutic agent for human AAA."

Journal • Preclinical